header
Image from OpenLibrary

Cancer chemoprevention by Metformin Hydrochloride compared to placebo in oral potentially malignant lesions : A randomized clinical trial (part I) / Ahmed Adel Mohamed Abdelazim ; Supervised Fat{u2019}heya Mohamed Zahran , Gihane Gharib Madkor , Heba Ahmed Farrag

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Ahmed Adel Mohamed Abdelazim , 2021Description: 201 P. : charts , facsimiles ; 25cmOther title:
  • الوِقايَةٌ الكِيمْيائِيَّة من السرطان بواسطة هيدروكلوريد الميتفورمن مقارنة بالغُفْل في آفات الفم القابلة للتسرطن : دراسة إكلينيكيّة على عينات مختارة عشوائياً - الجزء الأول [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (Ph.D.) - Cairo University - Faculty of Oral and Dental Medicine - Department of Periodontology Summary: Aim: The aim of this study was to compare the effect of metformin hydrochloride on potentially malignant to placebo regarding its efficacy in regression or suppression of the progress into frank cancer. Methodology: This trial was a multicentre, triple{u00AD}blind, placebo{u00AD}controlled, randomized phase II trial. 40 non{u00AD}diabetic adult patients clinically and histologically diagnosed with OPMD were enrolled into the study. Eligible patients were randomly assigned (1:1) to receive oral met{u00AD} formin (500 mg daily) or identical placebo tablets by a stratified computer{u00AD}based randomization method for a duration of 3 months. All patients, clinicians, and outcome assessors were masked to drug allocation until the end of the trial. Recommended standard health and dental care were given to both groups.Clinical data, biopsies, immunohistochemical staining of cyclin D1, and RT{u00AD}qPCR quantification of tissue and salivary miRNA{u00AD}21 were performed for all groups at baseline and at three months point. Results: The current study showed that metformin was effective as a cancer chemopreven{u00AD} tive agent in controlling some of the molecular mechanisms that could lead to the the malignant transformation of OPMDs. Clinical lesion size, nuclear expression of cyclin D1, and tissue and salivary levels of cancer{u00AD}associated miRNA{u00AD}21 showed a statistically significant reduction in the metformin group compared to the placebo group. Cyclin D1 and miRNA{u00AD}21 correlated well to the degree of epithelial dysplasia, while toluidine blue color intensity was of limited value as a prognostic aid in OPMD. miRNA{u00AD}21 demonstrated a positive correlation between tissue and saliva levels, highlighting the emerging role of salivary transcriptomics in the field of OPMDs and oral cancer
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.09.08.Ph.D.2021.Ah.C (Browse shelf(Opens below)) Not for loan 01010110084275000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.09.08.Ph.D.2021.Ah.C (Browse shelf(Opens below)) 84275.CD Not for loan 01020110084275000

Thesis (Ph.D.) - Cairo University - Faculty of Oral and Dental Medicine - Department of Periodontology

Aim: The aim of this study was to compare the effect of metformin hydrochloride on potentially malignant to placebo regarding its efficacy in regression or suppression of the progress into frank cancer. Methodology: This trial was a multicentre, triple{u00AD}blind, placebo{u00AD}controlled, randomized phase II trial. 40 non{u00AD}diabetic adult patients clinically and histologically diagnosed with OPMD were enrolled into the study. Eligible patients were randomly assigned (1:1) to receive oral met{u00AD} formin (500 mg daily) or identical placebo tablets by a stratified computer{u00AD}based randomization method for a duration of 3 months. All patients, clinicians, and outcome assessors were masked to drug allocation until the end of the trial. Recommended standard health and dental care were given to both groups.Clinical data, biopsies, immunohistochemical staining of cyclin D1, and RT{u00AD}qPCR quantification of tissue and salivary miRNA{u00AD}21 were performed for all groups at baseline and at three months point. Results: The current study showed that metformin was effective as a cancer chemopreven{u00AD} tive agent in controlling some of the molecular mechanisms that could lead to the the malignant transformation of OPMDs. Clinical lesion size, nuclear expression of cyclin D1, and tissue and salivary levels of cancer{u00AD}associated miRNA{u00AD}21 showed a statistically significant reduction in the metformin group compared to the placebo group. Cyclin D1 and miRNA{u00AD}21 correlated well to the degree of epithelial dysplasia, while toluidine blue color intensity was of limited value as a prognostic aid in OPMD. miRNA{u00AD}21 demonstrated a positive correlation between tissue and saliva levels, highlighting the emerging role of salivary transcriptomics in the field of OPMDs and oral cancer

Issued also as CD

There are no comments on this title.

to post a comment.